Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.

Villanueva FN, Pérez-Simón JA, Silva FF, Caballero-Velázquez TT, Sánchez-Guijo FF, Cañizo CC, Vázquez LL, Caballero DD, San Miguel JF.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1331-6. doi: 10.1016/j.bbmt.2009.05.018. Epub 2009 Jul 22.

2.

Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD).

Castilla C, Pérez-Simón JA, Sanchez-Guijo FM, Díez-Campelo M, Ocio E, Pérez-Persona E, López-Villar O, Vazquez L, Caballero D, San Miguel JF.

Biol Blood Marrow Transplant. 2006 Sep;12(9):936-41.

3.

Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease.

Iyer RV, Hahn T, Roy HN, Battiwalla M, Cooper M, Anderson B, Paplham P, Brown K, Bambach B, Segal BH, McCarthy PL Jr.

Biol Blood Marrow Transplant. 2005 Aug;11(8):587-92.

4.

The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group.

Takashima S, Eto T, Shiratsuchi M, Hidaka M, Mori Y, Kato K, Kamezaki K, Oku S, Henzan H, Takase K, Matsushima T, Takenaka K, Iwasaki H, Miyamoto T, Akashi K, Teshima T.

Intern Med. 2014;53(12):1315-20. Epub 2014 Jun 15.

5.

A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.

Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB.

Blood. 2007 May 15;109(10):4557-63. Epub 2007 Jan 23.

7.

Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.

Andree H, Hilgendorf I, Leithaeuser M, Junghanss C, Holzhueter S, Loddenkemper C, Steiner B, Freund M, Wolff D.

Bone Marrow Transplant. 2008 Oct;42(8):541-6. doi: 10.1038/bmt.2008.209. Epub 2008 Jul 21.

PMID:
18641680
8.

Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1576-82. doi: 10.1016/j.bbmt.2015.04.023. Epub 2015 May 16.

9.

Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease.

Baehr PH, Levine DS, Bouvier ME, Hockenbery DM, Gooley TA, Stern JG, Martin PJ, McDonald GB.

Transplantation. 1995 Dec 15;60(11):1231-8.

PMID:
8525516
10.

Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.

Busca A, Saroglia EM, Lanino E, Manfredini L, Uderzo C, Nicolini B, Messina C, Rabusin M, Miniero R.

Bone Marrow Transplant. 2000 May;25(10):1067-71.

PMID:
10828867
12.

Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.

Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF; Grupo Español de Trasplante Hematopoyético (GETH)..

Biol Blood Marrow Transplant. 2008 Jun;14(6):664-71. doi: 10.1016/j.bbmt.2008.03.007.

13.

The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease.

Doan PL, Chao NJ.

Drugs. 2009 Jul 9;69(10):1339-50. doi: 10.2165/00003495-200969100-00004. Review.

PMID:
19583452
14.

[Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].

Chen H, Liu KY, Liu DH, Xu LP, Han W, Chen YH, Huang XJ.

Zhonghua Yi Xue Za Zhi. 2008 Aug 5;88(30):2127-30. Chinese.

PMID:
19080474
15.

Oral beclomethasone dipropionate as an initial treatment for stages 1-2 gastrointestinal tract acute graft-versus-host disease following unrelated cord blood transplantation.

Yamamoto H, Uchida N, Uchida Y, Nishida A, Ota H, Kageyama K, Nasu I, Wada S, Kaji D, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Matsuno N, Yamamoto G, Masuoka K, Izutsu K, Wake A, Yoneyama A, Makino S, Ito T, Hayashi M, Taniguchi S.

Ann Hematol. 2015 Dec;94(12):2073-5. doi: 10.1007/s00277-015-2483-z. Epub 2015 Sep 16. No abstract available.

PMID:
26374433
16.

Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.

Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J.

Biol Blood Marrow Transplant. 2009 Aug;15(8):919-29. doi: 10.1016/j.bbmt.2009.04.004. Epub 2009 Jun 10.

17.

[Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].

Zhang WP, Wang JM, Ju XP, Song XM, Tong SP, Li HM.

Zhonghua Xue Ye Xue Za Zhi. 2003 Mar;24(3):129-33. Chinese.

PMID:
12697123
18.

[Prophylaxis and treatment of chronic graft versus host disease].

Huang K, Li Y, Huang SL, Fang JP, Zhou DH, Chen C.

Zhonghua Er Ke Za Zhi. 2005 Mar;43(3):174-7. Chinese.

PMID:
15833186
19.

[Analysis of blood concentrations following oral administration of beclomethasone dipropionate for gut GVHD].

Ito T, Watanabe K, Nasu I, Ino K, Minowa M, Furusawa M, Okuno Y, Uchida Y, Miyazaki Y, Tamura H, Hasebe S, Takagi S, Yamamoto H, Matsuno N, Uchida N, Masuoka K, Wake A, Makino S, Taniguchi S, Hayashi M.

Gan To Kagaku Ryoho. 2010 Feb;37(2):267-70. Japanese.

PMID:
20154483
20.

Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.

Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, Lee KB.

Eur J Haematol. 2004 Jul;73(1):56-61.

PMID:
15182339

Supplemental Content

Support Center